Traws Pharma (NASDAQ:TRAW) Earns “Buy” Rating from HC Wainwright

Traws Pharma (NASDAQ:TRAW)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 403.14% from the stock’s previous close.

Several other analysts have also recently weighed in on the company. LADENBURG THALM/SH SH raised Traws Pharma to a “strong-buy” rating in a report on Friday, January 30th. Weiss Ratings cut Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.00.

Traws Pharma Price Performance

TRAW opened at $1.59 on Wednesday. The company has a fifty day moving average price of $1.68 and a 200-day moving average price of $1.84. The firm has a market capitalization of $16.15 million, a P/E ratio of -0.94 and a beta of 1.47. Traws Pharma has a one year low of $1.00 and a one year high of $3.27.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.39. On average, analysts expect that Traws Pharma will post -2.51 earnings per share for the current year.

Insider Transactions at Traws Pharma

In other news, major shareholder Orbimed Advisors Llc bought 597,729 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was acquired at an average price of $1.67 per share, with a total value of $998,207.43. Following the completion of the purchase, the insider directly owned 1,203,250 shares in the company, valued at $2,009,427.50. This represents a 98.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 14.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Traws Pharma

A number of large investors have recently added to or reduced their stakes in TRAW. Squadron Capital Management LLC purchased a new position in Traws Pharma in the 4th quarter worth $806,000. Ikarian Capital LLC raised its position in Traws Pharma by 2,280.0% in the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after purchasing an additional 649,649 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Traws Pharma by 121.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares during the period. Boothbay Fund Management LLC purchased a new position in Traws Pharma in the 4th quarter worth $220,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Traws Pharma during the 4th quarter valued at about $175,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.